Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8086 to 8100 of 8899 results

  1. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)

    This guidance has been updated and replaced by NICE technology appraisal guidance 531.

    Withdrawn guidance

  2. Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (TA45)

    This guidance has been updated and replaced by NICE technology appraisal guidance 91.

    Withdrawn guidance

  3. Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure (TA48)

    This guidance has been updated and replaced by NICE guideline NG107 

    Withdrawn guidance

  4. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 655. 

    Withdrawn guidance

  5. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

    This guidance has been updated and replaced by NICE technology appraisal guidance 713.

    Withdrawn guidance

  6. Venetoclax for treating chronic lymphocytic leukaemia (TA487)

    This guidance has been updated and replaced by NICE technology appraisal guidance 796.

    Withdrawn guidance

  7. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

    Withdrawn guidance

  8. Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.

    Withdrawn guidance

  9. Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

    This guidance has been updated and replaced by NICE technology appraisal guidance 736.

    Withdrawn guidance

  10. Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

    This guidance has been updated and replaced by NICE technology appraisal guidance 629.

    Withdrawn guidance

  11. Newer drugs for epilepsy in children (TA79)

    This guideline has been updated and replaced by NICE guideline CG137.

    Withdrawn guidance

  12. Hearing disability - hearing aids (TA8)

    This guidance has been withdrawn.

    Withdrawn guidance

  13. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

    This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.

    Withdrawn guidance

  14. Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1038.

    Withdrawn guidance

  15. Crizanlizumab for preventing sickle cell crises in sickle cell disease (TA743)

    NICE has withdrawn this guidance. Novartis will stop marketing crizanlizumab (Adakveo) because its marketing authorisation has been withdrawn by the Medicines and Healthcare products Regulatory Agency (MHRA). Novartis has issued a direct letter to healthcare professionals specialising in haematology. No new people will start taking crizanlizumab in the UK. Healthcare professionals should discuss alternative treatment options with people currently having crizanlizumab.

    Withdrawn guidance